Rare Focus Jazz concentrates on rare diseases with limited options; target centers of excellence and patient advocacy groups to enable access programs, and craft payer friendly value propositions for neurology and oncology settings.

Territory Licensing Exclusive rights in different territories for zanidatamab and SAN2355 create expansion opportunities; pursue additional in license or co development deals with BeOne Medicines, Saniona, and other partners to broaden coverage.

Neuro Pipeline SAN2355 targets epilepsy and neurological disorders; leverage Xywav presence and neurology networks to engage clinicians, run trials, and secure payer acceptance for new indications.

Strategic Partnerships Jazz collaboration model with Zymeworks shows potential to accelerate growth; identify new biotech and academic partners for co development and licensing in rare diseases and targeted therapies.

Data Enablement Utilize the modern tech stack including CRM and analytics to drive data driven outreach, market insights, and efficient product launches across regions.